{"id":1047,"date":"2025-06-05T16:19:53","date_gmt":"2025-06-05T16:19:53","guid":{"rendered":"https:\/\/telyrx.com\/blog\/?p=1047"},"modified":"2026-03-13T20:42:29","modified_gmt":"2026-03-13T20:42:29","slug":"compounded-glp1s-fda-ban","status":"publish","type":"post","link":"https:\/\/telyrx.com\/blog\/news-press\/news\/compounded-glp1s-fda-ban\/","title":{"rendered":"Can You Trust Compounded GLP-1s? What the FDA Ban Means for You"},"content":{"rendered":"\n

Reviewed by Adam Gardner<\/a>, Licensed Pharmacist & COO of TelyRx<\/em><\/p>\n\n\n\n

\"A\n
A man taking an injectable Mounjaro pen out of a medicine cabinet.<\/figcaption><\/figure>\n\n\n\n

Feeling uncertain about the future of<\/span> your GLP-1 <\/span>medication? You\u2019re not alone\u2014<\/span>thousands of patients using compounded semaglutide <\/span>are facing the same confusion.<\/span>\u00a0<\/span><\/p>

In the aftermath of the <\/span>May 22nd FDA ban<\/span><\/a>, patients nationwide<\/span> are suddenly discovering that the semaglutide<\/span> they’ve been taking\u2014the one helping them lose weight and feel more in control of their health\u2014isn’t what they thought it was.<\/span>\u00a0<\/span><\/p>

We came across a recent <\/span>study that examined websites selling compounded GLP-1s<\/span><\/a> between July and September of last year. The findings? Genuinely concerning. Of 79 pharmacies identified, about 14% didn\u2019t disclose they were selling compounded versions, and nearly 37% implied or outright falsely claimed that the drugs were FDA-approved.\u00a0<\/span>\u00a0<\/span><\/p>

What\u2019s more, almost half the sites omitted critical information about potential side effects, and 40% made claims beyond what\u2019s stated in FDA-approved labels. This combination of false claims and minimal regulation with compounded medications translates into a real risk for patients.\u00a0\u00a0<\/span>\u00a0<\/span><\/p>

So, when the FDA officially pulled the plug on compounded GLP-1s recently, it left many of us wondering: Do<\/em><\/span>\u00a0I need to stop my treatment? How much will FDA-approved alternatives cost?<\/span><\/i> And most importantly\u2014<\/span>Why is this happening now, when I\u2019m finally seeing results?<\/span><\/i>\u00a0<\/span><\/p>

Let\u2019s walk through what\u2019s happening with this recent FDA ban, why it matters for your health journey, and what concrete steps you can take now to keep your progress going without interruption.<\/span>\u00a0<\/span><\/p>\n\n\n\n

\"A\n
Compounded GLP-1s often come in a liquid vile.<\/figcaption><\/figure>\n\n\n\n

In April 2024, <\/span>the FDA banned compounding pharmacies<\/span><\/a> from producing versions of semaglutide (the active ingredient in medications like Ozempic\u00ae and Wegovy\u00ae). While compounded medications can be permitted during shortages, they must use FDA-approved ingredients that have passed proper testing. <\/span>The problem? <\/span><\/p>

Many pharmacies were using unapproved forms like semaglutide sodium or acetate which were never properly evaluated or authorized for humans. <\/span>Our board-certified pharmacist Adam Gardner explains it perfectly:<\/span>\u00a0<\/span><\/p>

“The difference between FDA-approved medications and compounded versions is night and day. FDA-approved medications undergo years of clinical trials before they ever reach a patient. They’re manufactured with strict quality controls and come in pre-filled pens to ensure dosing accuracy.”<\/span><\/p><\/blockquote>

The FDA\u2019s decision to ban compounded semaglutide came after receiving more than 775 adverse event reports linked to non-branded formulations, including hospitalizations from incorrect dosing. Upon investigation, they found that many issues stemmed from the manual dosing process. <\/span><\/p>

Compounded versions typically come in vials that you must measure yourself with a syringe. And when we\u2019re dealing with medications that affect metabolism and hunger signals, even small measurement errors can lead to serious health consequences.\u00a0\u00a0<\/span>\u00a0<\/span><\/p>

Importantly, the ban was not sudden. The FDA had temporarily permitted compounded semaglutide during the national shortage, but with supply now stabilized\u2014and expected to remain stable\u2014<\/span><\/span>they t<\/span>ook<\/span> <\/span>decisive steps to protect public health by removing unregulated, potentially unsafe alternatives from the market.<\/span><\/span>\u00a0<\/span><\/p>\n\n\n\n

\"A\n
A manufacturing conveyer belt of compounded GLP-1 bottles.<\/figcaption><\/figure>\n\n\n\n

If you\u2019ve searched online for weight loss solutions recently, you’ve probably seen countless ads for \u201cAffordable semaglutide,\u201d or “Ozempic alternatives without the wait.” Many providers promoted these with promises of immediate availability and low costs\u2014particularly appealing if you couldn\u2019t access or afford FDA-approved versions.\u00a0\u00a0<\/span>\u00a0<\/span><\/p>\n\n\n\n

Compounded GLP-1s seemed like the perfect solution: more readily available, often cheaper, and promising the same results. Clinics and telehealth companies jumped at the opportunity, offering these medications as a way to bypass waitlists and high prices.<\/span>\u00a0<\/span><\/p>\n\n\n\n

But here\u2019s the catch: Many patients didn’t realize they weren’t getting the same medication. Contrary to widely held misconceptions, compounded versions are not equivalent to generics; they\u2019re entirely different chemical formulations with their own unique risks and unknowns.<\/span>\u00a0<\/span><\/p>\n\n\n\n

\n\n\n\n

“There’s no comprehensive tracking system for side effects with these compounds,” Gardner notes. “Problems often go unreported. And nobody’s studied the long-term effects of these compounds.\u201d<\/span>\u00a0<\/span><\/p>\n\n\n\n<\/blockquote>\n\n\n\n

\"A\n
Compounded GLP-1 does often require you to measure dosage amounts in a syringe.<\/figcaption><\/figure>\n\n\n\n

If <\/span><\/span>you\u2019ve<\/span> been<\/span> <\/span>using a compounded GLP-1, this regulatory change <\/span><\/span>has <\/span><\/span>directl<\/span>y affect<\/span><\/span>ed<\/span><\/span> your treatment plan. <\/span><\/span>And <\/span>since<\/span> the May 2025 <\/span>deadline has already passed<\/span><\/span>, healthcare professionals recommend <\/span><\/span>acting <\/span><\/span>now rather than waiting until <\/span><\/span>your supply runs out<\/span><\/span>.<\/span><\/span>\u00a0<\/span><\/p>

Here’s why acting sooner matters:<\/span>\u00a0<\/span><\/p>

You don’t want to suddenly stop taking <\/span>GLP-1s<\/span>\u2014<\/span>doing so<\/span> can lead to rebound weight g<\/span>ain<\/span>, g<\/span>a<\/span>strointestinal effects<\/span> and <\/span>overal<\/span>l <\/span>he<\/span>alth risks<\/span>. <\/span>Plus, y<\/span>ou’ll need time to adjust to new medication schedules and dosing<\/span>. And<\/span><\/span>, the more time that passes<\/span> after the deadline,<\/span><\/span> the more<\/span>\u00a0l<\/span><\/span>ikely <\/span><\/span>there is <\/span><\/span>to be<\/span> a bottleneck of patients all trying to switch at once<\/span>.<\/span><\/span>\u00a0<\/span><\/p>

As Gardner puts it:<\/span><\/p>

“It’s like trying to funnel thousands of cars from a six-lane highway back into two lanes. Even with increased capacity, there could be delays. My advice? Get in the queue now.”<\/span>\u00a0<\/span><\/p><\/blockquote>

If you’re unsure whether your current medication is compounded or FDA-approved, here are some telltale signs:<\/span>\u00a0<\/span><\/p>